公开(公告)号：US20190152946A1

公开(公告)日：2019-05-23

申请号：US16308542

申请日：2017-06-08

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： John David HARLING ,  Christopher TINWORTH

IPC: C07D401/12 ,  A61P35/00 ,  C07K5/12 ,  A61K47/64 ,  A61K47/65

Abstract: A method of treating disorders associated with aberrant kinase activity, wherein the kinase is. IRAK3, GAK, TEC, PTK2B(PYK2), AURKA, RPS6KA1(RSK3), MAPK9(JNK2), BTK, PTK2 or AKT2, said method comprising degrading said kinase.

公开(公告)号：US20190210996A1

公开(公告)日：2019-07-11

申请号：US16326234

申请日：2017-08-16

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： John David HARLING ,  Christopher TINWORTH

IPC: C07D401/14 ,  A61K47/64 ,  A61K47/66 ,  A61K45/06

CPC classification number: C07D401/14 ,  A61K45/06 ,  A61K47/64 ,  A61K47/66 ,  A61P35/00

Abstract: A method of treating disorders associated with aberrant kinase activity, wherein the kinase is. Adaptor-associated protein kinase 1 (AAK1), Aurora Kinase A (AURKA), Aurora Kinase B (AURKB), Bruton's Tyrosine Kinase (BTK), Interleukin-1 receptor-associated kinase 3 (IRAK3), Protein tyrosine kinase 2 beta (PTK2B), Tyrosine-protein kinase Tec (TEC), Serine/threonine-protein kinase Wee1 (WEE1), Cyclin G-associated kinase (GAK), Large Tumour suppressor 1 Kinase (LATS1), Focal Adhesion Kinase (PTK2), Ribosomal protein S6 kinase alpha-1 (RPS6KA1) said method comprising degrading said kinase.